Sintilimab
Highest phase reached
Phase 3
Drug type
Antibody
- Listing at source
- Listed
- Highest phase reached
- Phase 3
- Drug type
- Antibody
- Drug name
- Sintilimab
- tyvyt
- Tyvyt
- albumin bound paclitaxel cisplatin sintilimab
- anti pd 1 monoclonal antibody ibi308
- ANTI-PD-1 MONOCLONAL ANTIBODY IBI308
- ibi 308
- IBI 308 injection
- IBI-308
- ibi308
- Ibi308
- IBI308
- IBI308 200mg
- immunoglobulin g4 anti human programmed cell death protein 1 human monoclonal ibi308 gamma 4 chain disulfide with human monoclonal ibi308 kappa chain dimer
- IMMUNOGLOBULIN G4, ANTI-(HUMAN PROGRAMMED CELL DEATH PROTEIN 1) (HUMAN MONOCLONAL IBI308 .GAMMA.4-CHAIN), DISULFIDE WITH HUMAN MONOCLONAL IBI308 .KAPPA.-CHAIN, DIMER
- Immunotherapy (Sintilimab)
- sintilimab
- Sintilimab
- Sintilimab (18 cycles)
- Sintilimab (9 cycles)
- sintilimab (after the change)
- Sintilimab (approved)
- sintilimab (before the change)
- Sintilimab (M1b)
- Sintilimab (PD-1 Antibody)
- sintilimab [INN]
- SINTILIMAB [USAN]
- Sintilimab [WHO-DD]
And 6 more, listed on the interactive page.
- CAS registry numbers
- 2072873-06-2
- ChEMBL ID
- CHEMBL4297829
- FDA ingredient codes (UNII)
- 8FU7FQ8UPK
- Patents
- 0
- Designations
- 2
- First in class
- No
- Fast track
- No
- Breakthrough designation
- No
- Orphan designation
- No
- Priority review
- No
- Orphan exclusivity
- No
- Accelerated approval
- No
- Pharmacology name
- sintilimab
- Type
- Antibody
- Drug name stem
- -mab
- Approval recorded by Guide to Pharmacology
- Yes
- Mechanism
- Programmed cell death protein 1 antagonist
- Action type
- Antagonist
- Target
- Programmed cell death protein 1
- Protein identifier
- Q15116
- Action
- Binding
- Action type
- Binding
- Target
- programmed cell death 1 (CD279)
- Gene symbol
- PDCD1
- Protein identifier
- Q15116
- Median affinity
- 9.6
- Affinity units
- pKd
- Primary target
- Yes
Open Targets mechanisms
- Mechanism
- Programmed cell death protein 1 antagonist
- Action type
- Antagonist
- Target
- Programmed cell death protein 1
- Condition
- Stomach Neoplasms
- Highest recorded phase
- 3
- Condition identifier
- EFO:0000178
- Subject identifier
- D013274
- Condition
- Carcinoma, Squamous Cell
- Highest recorded phase
- 2
- Condition identifier
- EFO:0000181
- Subject identifier
- D002294
- Condition
- Carcinoma, Hepatocellular
- Highest recorded phase
- 3
- Condition identifier
- EFO:0000182
- Subject identifier
- D006528
- Condition
- Hodgkin Disease
- Highest recorded phase
- 3
- Condition identifier
- EFO:0000183
- Subject identifier
- D006689
- Condition
- Squamous Cell Carcinoma of Head and Neck
- Highest recorded phase
- 2
- Condition identifier
- EFO:0000199
- Subject identifier
- D000077195
- Condition
- Lymphoma, T-Cell, Peripheral
- Highest recorded phase
- 2
- Condition identifier
- EFO:0000211
- Subject identifier
- D016411
- Condition
- Immunoblastic Lymphadenopathy
- Highest recorded phase
- 2
- Condition identifier
- EFO:0000255
- Subject identifier
- D007119
- Condition
- Carcinoma
- Highest recorded phase
- 1
- Condition identifier
- EFO:0000313
- Subject identifier
- D002277
- Condition
- Adenocarcinoma, Clear Cell
- Highest recorded phase
- 2
- Condition identifier
- EFO:0000348
- Subject identifier
- D018262
- Condition
- Carcinoma, Renal Cell
- Highest recorded phase
- 2
- Condition identifier
- EFO:0000349
- Subject identifier
- D002292
- Condition
- Colorectal Neoplasms
- Highest recorded phase
- 3
- Condition identifier
- EFO:0000365
- Subject identifier
- D015179
- Condition
- Lymphoma, Large B-Cell, Diffuse
- Highest recorded phase
- 2
- Condition identifier
- EFO:0000403
- Subject identifier
- D016403
- Condition
- Stomach Neoplasms
- Highest recorded phase
- 3
- Condition identifier
- EFO:0000503
- Subject identifier
- D013274
- Condition
- Glioblastoma
- Highest recorded phase
- 2
- Condition identifier
- EFO:0000519
- Subject identifier
- D005909
- Condition
- Lymphoma
- Highest recorded phase
- 2
- Condition identifier
- EFO:0000574
- Subject identifier
- D008223
- Condition
- Mesothelioma
- Highest recorded phase
- 2
- Condition identifier
- EFO:0000588
- Subject identifier
- D008654
- Condition
- Neoplasms
- Highest recorded phase
- 2
- Condition identifier
- EFO:0000616
- Subject identifier
- D009369
- Condition
- Neuroblastoma
- Highest recorded phase
- 2
- Condition identifier
- EFO:0000621
- Subject identifier
- D009447
- Condition
- Carcinoma, Renal Cell
- Highest recorded phase
- 2
- Condition identifier
- EFO:0000681
- Subject identifier
- D002292
- Condition
- Sarcoma
- Highest recorded phase
- 2
- Condition identifier
- EFO:0000691
- Subject identifier
- D012509
- Condition
- Small Cell Lung Carcinoma
- Highest recorded phase
- 2
- Condition identifier
- EFO:0000702
- Subject identifier
- D055752
- Condition
- Carcinoma, Squamous Cell
- Highest recorded phase
- 2
- Condition identifier
- EFO:0000707
- Subject identifier
- D002294
- Condition
- Carcinoma, Squamous Cell
- Highest recorded phase
- 2
- Condition identifier
- EFO:0000708
- Subject identifier
- D002294
- Condition
- Uterine Cervical Neoplasms
- Highest recorded phase
- 2
- Condition identifier
- EFO:0001061
- Subject identifier
- D002583
- Condition
- Uterine Cervical Neoplasms
- Highest recorded phase
- 2
- Condition identifier
- EFO:0001416
- Subject identifier
- D002583
And 39 more, listed on the interactive page.
- Condition identifier
- EFO_0000178
- Highest recorded phase
- 2
- Condition identifier
- EFO_0000181
- Highest recorded phase
- 2
- Condition identifier
- EFO_0000182
- Highest recorded phase
- 3
- Condition identifier
- EFO_0000183
- Condition identifier
- EFO_0000199
- Highest recorded phase
- 2
- Condition identifier
- EFO_0000255
- Highest recorded phase
- 2
- Condition identifier
- EFO_0000313
- Highest recorded phase
- 2
- Condition identifier
- EFO_0000348
- Highest recorded phase
- 2
- Condition identifier
- EFO_0000349
- Highest recorded phase
- 2
- Condition identifier
- EFO_0000403
- Highest recorded phase
- 2
- Condition identifier
- EFO_0000503
- Highest recorded phase
- 3
- Condition identifier
- EFO_0000519
- Highest recorded phase
- 2
- Condition identifier
- EFO_0000574
- Highest recorded phase
- 2
- Condition identifier
- EFO_0000616
- Highest recorded phase
- 2
- Condition identifier
- EFO_0000621
- Highest recorded phase
- 2
- Condition identifier
- EFO_0000681
- Condition identifier
- EFO_0000702
- Highest recorded phase
- 2
- Condition identifier
- EFO_0000707
- Highest recorded phase
- 2
- Condition identifier
- EFO_0000708
- Highest recorded phase
- 2
- Condition identifier
- EFO_0001061
- Highest recorded phase
- 2
- Condition identifier
- EFO_0001416
- Highest recorded phase
- 2
- Condition identifier
- EFO_0002618
- Highest recorded phase
- 2
- Condition identifier
- EFO_0002913
- Highest recorded phase
- 2
- Condition identifier
- EFO_0003060
- Highest recorded phase
- 3
- Condition identifier
- EFO_0003826
- Highest recorded phase
- 2
And 123 more, listed on the interactive page.
- Event
- abdominal infection
- Reports
- 3
- Reporting signal score
- 11.669
- Event
- abdominal pain
- Reports
- 17
- Reporting signal score
- 18.1127
- Event
- adrenal insufficiency
- Reports
- 6
- Reporting signal score
- 16.3508
- Event
- alanine aminotransferase increased
- Reports
- 22
- Reporting signal score
- 47.4406
- Event
- anaemia
- Reports
- 36
- Reporting signal score
- 63.8602
- Event
- ascites
- Reports
- 5
- Reporting signal score
- 8.65812
- Event
- aspartate aminotransferase increased
- Reports
- 22
- Reporting signal score
- 49.9324
- Event
- blood bilirubin increased
- Reports
- 10
- Reporting signal score
- 22.606
- Event
- blood creatinine increased
- Reports
- 7
- Reporting signal score
- 8.53214
- Event
- cardiotoxicity
- Reports
- 3
- Reporting signal score
- 6.87168
- Event
- cerebral radiation injury
- Reports
- 1
- Reporting signal score
- 7.86259
- Event
- constipation
- Reports
- 12
- Reporting signal score
- 12.3325
- Event
- cytokine increased
- Reports
- 1
- Reporting signal score
- 9.24878
- Event
- cytokine release syndrome
- Reports
- 3
- Reporting signal score
- 6.69213
- Event
- cytopenia
- Reports
- 4
- Reporting signal score
- 9.58312
- Event
- decreased appetite
- Reports
- 31
- Reporting signal score
- 60.7928
- Event
- dermatitis
- Reports
- 5
- Reporting signal score
- 11.7464
- Event
- diarrhoea
- Reports
- 43
- Reporting signal score
- 50.2813
- Event
- endocrine toxicity
- Reports
- 1
- Reporting signal score
- 6.47672
- Event
- fatigue
- Reports
- 32
- Reporting signal score
- 26.6971
- Event
- gastrointestinal disorder
- Reports
- 7
- Reporting signal score
- 10.0885
- Event
- gastrointestinal haemorrhage
- Reports
- 8
- Reporting signal score
- 9.42674
- Event
- gastrointestinal toxicity
- Reports
- 3
- Reporting signal score
- 8.58975
- Event
- gingival bleeding
- Reports
- 3
- Reporting signal score
- 6.14527
- Event
- granulocyte count decreased
- Reports
- 2
- Reporting signal score
- 7.48963
And 46 more, listed on the interactive page.
- NCT02937116
- NCT03568539
- NCT03732430
- NCT04085185
- NCT04353830
- NCT04400851
- NCT05024968
- NCT05245916
- NCT03116152
- NCT03748134
- NCT03940001
- NCT03946969
- NCT03985046
- NCT04212598
- NCT04514835
- NCT04548440
- NCT04602013
- NCT04625543
- NCT05174325
- NCT05244798
- NCT05495152
- NCT06078657
- NCT06152978
- NCT06161909
- NCT06190639
And 247 more, listed on the interactive page.
- Prodrug
- No
- Chirality
- Single enantiomer
- Inorganic
- No
- Natural product
- No
- Component
- Glycosylation sites (N)
- Sequence
- Asn-297 $ Asn-297''''
- Component
- Heavy chain
- Type
- Protein
- Sequence
- QVQLVQSGAEVKKPGSSVKVSCKASGGTFSSYAISWVRQAPGQGLEWMGLIIPMFDTAGYAQKFQGRVAITVDESTSTAYMELSSLRSEDTAVYYCARAEHSSTGTFDYWGQGTLVTVSSASTKGPSVFPLAPCSRSTSESTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTKTYTCNVDHKPSNTKVDKRVESKYGPPCPPCPAPEFLGGPSVFLFPPKPKDTLMISRTPEVTCVVVDVSQEDPEVQFNWYVDGVEVHNAKTKPREEQFNSTYRVVSVLTVLHQDWLNGKEYKCKVSNKGLPSSIEKTISKAKGQPREPQVYTLPPSQEEMTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTTPPVLDSDGSFFLYSRLTVDKSRWQEGNVFSCSVMHEALHNHYTQKSLSLSLGK
- Component
- Light chain
- Type
- Protein
- Sequence
- DIQMTQSPSSVSASVGDRVTITCRASQGISSWLAWYQQKPGKAPKLLISAASSLQSGVPSRFSGSGSGTDFTLTISSLQPEDFATYYCQQANHLPFTFGGGTKVEIKRTVAAPSVFIFPPSDEQLKSGTASVVCLLNNFYPREAKVQWKVDNALQSGNSQESVTEQDSKDSTYSLSSTLTLSKADYEKHKVYACEVTHQGLSSPVTKSFNRGEC
- Component
- Disulfide bridges
- Sequence
- 22-96 $ 22''-96'' $ 23'-88' $ 23'''-88''' $ 134'-194' $ 134'''-194''' $ 134-214' $ 134''-214''' $ 147-203 $ 147''-203'' $ 226-226'' $ 229-229'' $ 261-321 $ 261''-321'' $ 367-425 $ 367''-425''
- Component
- Glycosylation sites (N)
- Sequence
- Asn-297 $ Asn-297''
Related records
Trials (569)
- A Biomarker Study for Predicting the Efficacy of Neoadjuvant Sintilimab Plus SOX for Gastric Adenocarcinoma.
- A Clinical Study of SHR-8068 Combined With Adebrelimab and Bevacizumab Versus Sintilimab or Atezolizumab Combined With Bevacizumab for the Treatment of Advanced Hepatocellular Carcinoma
- A Clinical Study of Sintilimab as Adjuvant Therapy in Node-positive ESCC
- A Clinical Study of Sintilimab Combined With Chemothrapy Versus Chemotherapy as Adjuvant Therapy for Gastric/Gastroesophageal Junction Adenocarcinoma
- A Clinical Study on the Efficacy and Safety of Fruquintinib in Combination With PD-1 Monoclonal Antibody and Chidamide in Refractory MSS Metastatic Colorectal Cancer
- A Clinical Study to Observe the Effectiveness and Safety of IBI310, Bevacizumab Combined With Sintilimab in the Treatment of Advanced Hepatocellular Carcinoma
- A Clinical Trial Evaluating the Efficacy and Safety of IBI310 in Combination With Sintilimab, for Neoadjuvant Treatment of MSI-H/dMMR Resectable Colon Cancer
- A Comparative Study to Evaluate the Effect of HSP-130, US-approved Neulasta and EU-approved Neulasta in Healthy Participants
- A Dose Escalation and Dose Expansion Clinical Study of STI-7349 in Subjects With Advanced Solid Tumors
- A Multicenter Phase II Randomized Trial of Limertinib Followed by Sintilimab and Chemotherapy vs. Limertinib Followed by Limertinib and Chemotherapy as Neoadjuvant Therapy in Resectable Stage II-IIIB EGFR-Mutant NSCLC
- A Multicenter, Prospective Clinical Trial With a Concurrent Control Evaluating Methotrexate Combined With Rituximab,Sintilimab and Pirtobrutinib vs. Investigator-Selected Standard of Care in Treatment-Naive PCNSL
- A Perioperative Sintilimab and Chemotherapy in Esophageal Squamous Cell Carcinoma
- A Phase 1b/2 Study of YL-13027 Combined With Sintilimab in Patients With Advanced Solid Tumors
- A Phase I Study of IBI325 in Patients With Advanced Solid Tumor
- A Phase I Study of IBI325 in Patients With Advanced Solid Tumor
- A Phase I Trial to Evaluate the Safety and Immunogenicity of Influenza Virus Split Vaccine (Adjuvant)
- A Phase II Clinical Study of Sintilimab Combined with Chemotherapy Followed by Concurrent Chemoradiotherapy for Locally Advanced Unresectable Esophageal Squamous Cell Carcinoma (ESCC) (NICE-CS)
- A Phase II Clinical Study of Surufatinib Combined With Sintilimab in the Treatment of Advanced Gastric Cancer
- A Phase II Clinical Study to Assess the Efficacy and Safety of IBI310 or Placebo Combined With Sintilimab for Advanced Cervical Cancer Subjects Who Have Failed or Cannot Tolerate First-line or Above Platinum-based Chemotherapy
- A Phase II Study of Anti-PD-1 Antibody, Sintilimab, as Second-line Therapy for Biomarker-selected Advanced or Metastatic NSCLC
In development for (68)
- Angioimmunoblastic T-cell lymphoma Phase 2
- Angiosarcoma Phase 2
- Biliary tract cancer Phase 2
- Breast cancer Phase 3
- Cancer Phase 2
- Carcinoma Phase 1
- Carcinoma of esophagus Phase 3
- Cervical adenocarcinoma Phase 2
- Cervical cancer Phase 2
- Cervical carcinoma Phase 2
- Cholangiocarcinoma Phase 2
- Classic Hodgkin lymphoma Phase 3
- Clear cell adenocarcinoma Phase 2
- Clear cell renal carcinoma Phase 2
- Colorectal adenocarcinoma Phase 3
- Colorectal cancer Phase 3
- Colorectal carcinoma Phase 3
- Colorectal neoplasm Phase 3
- Diffuse large B-cell lymphoma Phase 2
- Endometrial cancer Phase 2
Other linked conditions (2)
- Anaplastic meningioma
- Grade III meningioma
Targets (1)
- PDCD1 Programmed cell death protein 1 antagonist